Viking outlines ~$100M average quarterly cash usage as Phase III SUNRISE and VANQUISH advance (NASDAQ:VKTX)
· seekingalpha.com
Viking Therapeutics Q3 2026: Phase III VK2735 progress, obesity maintenance dosing data, and cash runway updates.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...